Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.
- Positive interim analysis supports XanaMIA trial continuation
- Open-label extension phase launched with strong participant uptake
- $16.8 million capital raising completed to fund operations
- Cash position extended beyond expected November 2026 topline results
- Regulatory and partnering activities advance alongside intellectual property protection
XanaMIA Trial Advances with Positive Interim Data
Actinogen Medical (ASX:ACW) has reached a significant milestone in its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial, with the independent Data Monitoring Committee (DMC) recommending the study continue without amendment following a confidential interim analysis in January 2026. The review encompassed unblinded safety and efficacy futility data from approximately 37% of the final dataset, involving 136 participants with at least one efficacy datapoint. This endorsement reduces clinical risk ahead of the anticipated topline results in November 2026.
The trial, which completed enrolment of its 247th participant in December 2025, remains blinded to all Actinogen staff and trial personnel. Participants continue receiving either Xanamem 10 mg or placebo over a 36-week treatment period. The XanaMIA study is designed as one of two pivotal trials potentially supporting regulatory approval, with Actinogen now planning a larger second pivotal trial expected to commence mid-2027 across multiple countries, including Australia.
Open-Label Extension Phase Gains Momentum
Following the randomized phase, the XanaMIA open-label extension (OLE) phase commenced on 31 March 2026, offering all eligible participants active Xanamem 10 mg daily for up to 25 months. Early uptake has been robust, with an 88% rollover rate of participants completing the main trial in recent weeks. This extension aims to collect long-term safety and observational efficacy data, including on the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) and cognitive function, which will feed into future regulatory submissions.
This development builds on the company’s earlier announcement of the OLE phase launch and underscores the commitment to comprehensive data collection beyond the placebo-controlled period open-label extension phase started.
Financial Position Strengthened by Capital Raising and Funding
Actinogen raised $16.8 million in February 2026 through a $12 million placement and a $4.8 million share purchase plan at 4.2 cents per share, following the positive interim analysis. The capital raising attracted strong support from both institutional and retail investors, with CEO Dr Steven Gourlay personally investing an additional $500,000, bringing his total private stake to approximately $2.45 million. Non-executive directors also participated with $167,000 in placement shares.
Alongside the equity raise, the company secured $4.3 million in non-dilutive funding from Endpoints Capital, drawn against its forecast FY26 research and development tax incentive (RDTI) rebate. Combined with a total RDTI rebate of $7.3 million received for FY2025, these funding sources have extended Actinogen’s cash runway well beyond the expected release of final XanaMIA results in November 2026.
Operating expenditure for the quarter was $7.4 million, predominantly directed towards the XanaMIA trial and its OLE phase. The company ended the quarter with $21.5 million in cash, providing a solid financial footing to support ongoing clinical and commercial activities. This follows earlier capital raising efforts and tax incentives that have underpinned the company’s development strategy Secures $16.8M to Power and Secures $7.36m R&D Rebate.
Advancing Regulatory and Commercial Readiness
Actinogen continues to engage proactively with regulators and the market as it prepares for potential accelerated approval pathways. The FDA’s recent policy shift to accept a single pivotal trial with adequate supporting evidence aligns with Actinogen’s strategy, and the company plans to explore this option post-November topline results. Engagement with the European Medicines Agency is scheduled for the second quarter of 2026, alongside ongoing discussions with other regulatory bodies.
Commercial planning efforts have intensified, including refining communication materials and strengthening relationships with key opinion leaders. The company is also actively pursuing partnering opportunities with regional and global firms, prioritising deals that offer strategic fit and attractive economic terms. Meanwhile, Actinogen is bolstering its intellectual property portfolio to extend protection against future generic competition, filing new patents covering composition, use, manufacturing, and patient selection.
The company’s presence at international conferences and investor forums, including the J.P. Morgan Healthcare Conference and the AD/PD 2026 International Conference, has reinforced external validation of Xanamem’s clinical and commercial potential in a competitive landscape.
Bottom Line?
Actinogen’s strengthened balance sheet and regulatory progress set the stage for a critical readout in November, but the success of accelerated approval and partnering efforts remains to be seen.
Questions in the middle?
- Will the FDA’s acceptance of a single pivotal trial materially accelerate Xanamem’s approval timeline?
- How will the planned larger second pivotal trial influence investor and partner confidence?
- What commercial partnerships might emerge ahead of or following the November topline results?